Cervical Cancer Screening and HPV Vaccination for Mothers and Daughters in Western Kenya
Tests HPV screening and vaccination in women and girls in rural Kenya.
Plain-language title generated from the registry record
Registry title: The Mother-Daughter Project: Merck-4
Key facts
- Where
- Eldoret, KenyaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 9 and 49 years old?
Source: NCT07240220, who can take part
Where in Kenya
- Moi UniversityEldoret, KenyaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Indiana University
- Trial code
- NCT07240220
- Record updated
- 10 November 2026
- Original description
This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya. The MDP project, since its initiation in 2018, has sought to develop a framework for the eradication of cervical cancer through effective screening of adult women and through the vaccination of female children.Read full original descriptionShow less
The Mother-Daughter Project: Inclusion of Difficult-to-reach Kenyan Families, and Studies of Factors Influencing the Immune Response to HPV Vaccination (Merck-4)
This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya. The MDP project, since its initiation in 2018, has sought to develop a framework for the eradication of cervical cancer through effective screening of adult women and through the vaccination of female children.
This project specifically aims to collect additional data on the ability for HR-HPV testing to detect premalignant lesions of the cervix, especially in HIV-infected women, to investigate and identify barriers leading to non-participation in previous MDP efforts, and to examine factors associated with the immune response to HPV vaccination among rural Kenyan girls.
Inclusion: ages 25 through 49 years; able/willing to sign informed consent; willing to participate in the community meetings; ages 9 through 14 years; have mother that is able/willing to sign informed consent for vaccination; can return for the second HPV vaccine dose in 6 - 12 months.
Exclusion: girls who are not willing or unable to return for the second HPV vaccine dose; pregnant; Kenyan Girls.
Kenyan Adult Women.